These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22133291)

  • 21. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X; Dufresne A; Villanueva C
    Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epothilones as Natural Compounds for Novel Anticancer Drugs Development.
    Villegas C; González-Chavarría I; Burgos V; Iturra-Beiza H; Ulrich H; Paz C
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P; Dumontet C
    Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
    Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
    Wakelee HA; Sikic BI
    Clin Lung Cancer; 2005 Sep; 7 Suppl 1():S6-12. PubMed ID: 16159420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer.
    Edelman MJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S30-4. PubMed ID: 19362944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New anti-tubulin agents.
    Felip E
    Suppl Tumori; 2002; 1(4):S17-8. PubMed ID: 12415808
    [No Abstract]   [Full Text] [Related]  

  • 35. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
    Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.
    Lee JJ; Kelly WK
    Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
    Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
    Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential clinical applications of epothilones: a review of phase II studies.
    Larkin JM; Kaye SB
    Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of epothilones in breast cancer therapy.
    Cianfrocca M
    Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.